anti-CD33/C-type lectin domain protein 12A CAR-NK cell therapy (Hangzhou Qihan Biotech)

N/A

Report date: 2025/06/11 10:38:25

Base Information

Drug Nameanti-CD33/C-type lectin domain protein 12A CAR-NK cell therapy (Hangzhou Qihan Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsImmunostimulantsNatural killer cells stimulants +[4]

TargetsMyeloid cell surface antigen CD33C-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesHangzhou Qihan Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Qihan Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A